Thank you, Mr. Chair.
As you know, Bill C-393 deals with a part of the Patent Act that deals with the use of patents for international humanitarian purposes to address public health problems. In it there are four schedules. One of them is a list of drugs that are approved under CAMR. The other three are lists of countries that have a slightly different status.
As you know, Bill C-393 in clause 15 sort of eliminated those, so we're left with one schedule at the back, which is a schedule of countries only. My aim, with a couple of these amendments, is to reintroduce the schedule 1 that is in the Patent Act and that lists eligible drugs under CAMR as approved by the Minister of Health.